NASDAQ · Biotechnology

NewcelX Ltd. (NCEL) Stock

$3.05 -2.09% NASDAQ: NCEL Healthcare

Valuation

MetricValue
Price$3.05
Market Cap$1.37M
P/E Ratio8.67
P/B Ratio2.77
P/S Ratio0.00
EPS (TTM)$-26.30
52-Week High$19.80
52-Week Low$1.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE21.75%
ROA14.90%
ROCE-114.73%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.06
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-15.0M$-12.0M$-4.0M$-2.0M
Net Profit$-12.0M$-16.0M$-12.0M$-2.0M$-8.0M
EPS$-8.10$-8.40$-3.20$-26.30$-2.16
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.0M$9.0M$2.0M$2.0M$11.0M
Total Liabilities$5.0M$6.0M$11.0M$1.0M$4.0M
Cash$5.0M$9.0M$1.0M$2.0M$2.0M
Borrowings$0$0$2.0M$0$0

Latest News

NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio GlobeNewswire · Jul 15, 2026 NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board GlobeNewswire · Jul 8, 2026 NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes GlobeNewswire · Jul 1, 2026 NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform GlobeNewswire · Jun 15, 2026 NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes GlobeNewswire · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-14.0M$-10.0M$-4.0M$-3.0M
Investing Cash Flow$0$-4.0M$0$0$2.0M
Financing Cash Flow$8.0M$7.0M$0$0$0
Net Cash Flow$5.0M$4.0M$-8.0M$1.0M$2.0M
Free Cash Flow$-15.0M$-14.0M$-10.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA-0.25
FCF Yield-223.31%
Quick Ratio0.32
Interest Coverage-1.21
Return 1Y-82.12%
Return 3Y-98.91%
Return 5Y-99.68%

Ownership

Insiders Held68.06%
Institutions Held1.14%
Institutions Float Held3.57%
Institutional HolderSharesReport Date
UBS Group AG6842026-03-31
Caitong International Asset Management Co., Ltd12026-03-31
Tower Research Capital LLC (TRC)1472026-03-31
Corecap Advisors, LLC32026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BACKIMAC Holdings, Inc. $0.02 +0.00% -0.01 $79484 0.00%
BCTXWBriaCell Therapeutics Corp. $0.00 — 0.00 $1695 0.00%
CELUCelularity Inc. $1.56 +6.85% -0.51 $45.16M 0.00%
CEROCERo Therapeutics Holdings, Inc. $0.01 -7.69% 0.00 $14464 0.00%
KTTAPasithea Therapeutics Corp. $0.47 +6.03% -0.19 $15.62M 0.00%

About NewcelX Ltd.

NewcelX Ltd. is led by CEO Ronen Twito, employs 11 people, headquartered in CH, publicly traded since 2025.

NewcelX Ltd. (NCEL) stock trades at $3.05 with a market capitalization of $1.37M. The stock is valued at a price-to-earnings (P/E) ratio of 8.67, price-to-book of 2.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.83 and $19.80, and currently trades 84.6% below its 52-week high.

On profitability, NewcelX Ltd. generates a return on equity (ROE) of 21.75% — well above the market average, a sign of a high-quality business, return on capital employed of -114.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides